We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Lays Out New Approaches for Trials of Fatty Liver Drugs
FDA Lays Out New Approaches for Trials of Fatty Liver Drugs
Drug sponsors should break down nonalcoholic fatty liver disease into three stages and focus on the most dangerous, the FDA suggests in new draft guidance issued Monday.